BioTech

Keros Appoints Anne Prener To Board Of Directors

June 26, 2026 — 04:48 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, announced on Thursday the appointment of Anne Prener to its Board of Directors, effective from July 1, 2026.

Prener currently serves as a Senior Innovation Advisor at the University of Copenhagen and as a non-executive director on the board of XSpray Pharma.

Previously, she held the position of Chief Executive Officer at Imbria Pharmaceuticals Inc. from July 2020 to September 2024. She also served as CEO of Freeline Therapeutics Holdings plc (FRLN), and Gyroscope Therapeutics Ltd.

Earlier in her career, Prener held several positions at Novo Nordisk A/S (NVO), most recently as Senior Vice President, Hemophilia R&D Portfolio. She has also served as a board member at Galecto, Inc. (GLTO), Rubius Therapeutics Inc. (RUBY), and Kaleido Biosciences, Inc. (KLDO).

KROS closed Thursday's trade at $10.41, down 4.76%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Keros Appoints Anne Prener To Board Of Directors

Tags

Latest Articles